Edict Acquisition (Consideration Transferred) (Details) (Edict Acquisition [Member], USD $) In Thousands, unless otherwise specified	0 Months Ended
	Feb. 17, 2012
Edict Acquisition [Member]
Business Acquisition [Line Items]
Cash purchase of equity	$ 20,659
Contingent purchase price liabilities	11,641	[1]
Cash paid for assumed indebtedness	4,300
Total purchase price	$ 36,600
Contingent liability, payment period (years)	18 months

[1] Contingent purchase price liabilities represent subsequent milestone payments related to successful FDA inspection of the Par Formulations manufacturing facility and ANDA filings. All contingent purchase price liabilities were paid in full within 18 months of the acquisition date.